GoAI
Get started
Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$72.67

+$1.15 · +1.61%

Aug 21, 4:00 PM ET

Pre-market

$72.90

+$0.23 · +0.32%

Aug 24, 4:40 AM ET

ESTA company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

64

Undervalued

Momentum

59

Neutral

Sentiment

45

Mixed

Risk resilience

64

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive plastic surgery. The company is primarily recognized for its silicone gel-filled breast implants, sold under the Motiva Implants brand. Among these are the Motiva Ergonomix and Motiva Ergonomix2, which are distinctive, gravity-sensitive, round, soft silicone-gel-filled implants. Furthermore, Establishment Labs provides the Motiva Flora Tissue Expander for breast tissue and distributes the Puregraft range of products, utilized for the harvesting and redistribution of autologous adipose tissue. The firm markets its offerings across Europe, Latin America, the Asia-Pacific region, and other global markets, leveraging both a direct sales force and exclusive distributors. Founded in 2004, Establishment Labs has its main office situated in Alajuela, Costa Rica.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Fillipo Peter Caldini
Listed since
Jul 19, 2018
Employees
1,004

Market position

Day range

Current $72.67

52-week range

Current $72.67

Open
$71.15
Previous close
$71.52
Volume
588.68K
1× average
Average volume
587.56K
Average daily volume
Market cap
2.14B USD
Beta
1.09
Market reference 1
50-day average
$86.0572
-15.56% below average
200-day average
$72.8889
-0.30% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.35B USD
P/E (TTM)
-55.55×
P/B (TTM)
101.31×
P/S (TTM)
8.7×
EV / EBITDA
-105.32×
Earnings yield
-2.37%
Free cash flow yield
-2.67%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
70.49%
Operating margin
-7.63%
Net margin
-15.82%
Return on equity
-216.86%
Return on assets
-14.30%
Return on invested capital
-11.87%

Financial health

Debt / equity
12.2×
Current ratio
3.04×
Altman Z-score
2.95
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends81%33%-15%-63%Gross margin, FY2021: 67.42%Gross margin, FY2022: 65.92%Gross margin, FY2023: 64.78%Gross margin, FY2024: 65.97%Gross margin, FY2025: 69.32%Operating margin, FY2021: -19.84%Operating margin, FY2022: -24.53%Operating margin, FY2023: -39.37%Operating margin, FY2024: -30.11%Operating margin, FY2025: -18.48%Net margin, FY2021: -32.47%Net margin, FY2022: -46.51%Net margin, FY2023: -47.53%Net margin, FY2024: -50.95%Net margin, FY2025: -24.19%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 67.42%. Gross margin FY2022 65.92%. Gross margin FY2023 64.78%. Gross margin FY2024 65.97%. Gross margin FY2025 69.32%. Operating margin FY2021 -19.84%. Operating margin FY2022 -24.53%. Operating margin FY2023 -39.37%. Operating margin FY2024 -30.11%. Operating margin FY2025 -18.48%. Net margin FY2021 -32.47%. Net margin FY2022 -46.51%. Net margin FY2023 -47.53%. Net margin FY2024 -50.95%. Net margin FY2025 -24.19%.

Income trends

Revenue

211.08M USD+27.14%

Operating income

−39.01M USD+21.96%

Net income

−51.06M USD+39.64%
Income trends across reported periods240.64M USD122.37M USD4.11M USD−114.16M USDRevenue, FY2021: 126.68M USDRevenue, FY2022: 161.7M USDRevenue, FY2023: 165.15M USDRevenue, FY2024: 166.03M USDRevenue, FY2025: 211.08M USDOperating income, FY2021: −25.14M USDOperating income, FY2022: −39.66M USDOperating income, FY2023: −65.03M USDOperating income, FY2024: −49.99M USDOperating income, FY2025: −39.01M USDNet income, FY2021: −41.14M USDNet income, FY2022: −75.21M USDNet income, FY2023: −78.5M USDNet income, FY2024: −84.6M USDNet income, FY2025: −51.06M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 126.68M USD. Revenue FY2022 161.7M USD. Revenue FY2023 165.15M USD. Revenue FY2024 166.03M USD. Revenue FY2025 211.08M USD. Operating income FY2021 −25.14M USD. Operating income FY2022 −39.66M USD. Operating income FY2023 −65.03M USD. Operating income FY2024 −49.99M USD. Operating income FY2025 −39.01M USD. Net income FY2021 −41.14M USD. Net income FY2022 −75.21M USD. Net income FY2023 −78.5M USD. Net income FY2024 −84.6M USD. Net income FY2025 −51.06M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue211.08M USD166.03M USD165.15M USD161.7M USD126.68M USD
Cost of goods sold64.77M USD56.5M USD58.17M USD55.11M USD41.28M USD
Gross profit146.31M USD109.53M USD106.98M USD106.6M USD85.4M USD
Research and development20.25M USD19.71M USD26.43M USD20.27M USD18.32M USD
Selling, general, and administrative165.07M USD139.81M USD145.58M USD125.98M USD92.23M USD
Operating expenses185.32M USD159.51M USD172M USD146.25M USD110.54M USD
Interest income423K USD1.48M USD1.02M USD87K USD23K USD
Interest expense25.26M USD20.83M USD15.39M USD11.76M USD9.06M USD
Depreciation and amortization10.47M USD7.58M USD4.88M USD4.17M USD4.11M USD
Operating income−39.01M USD−49.99M USD−65.03M USD−39.66M USD−25.14M USD
Net income−51.06M USD−84.6M USD−78.5M USD−75.21M USD−41.14M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
+2.24%
11 comparable reports
Latest EPS result
-0.39
Estimate -0.34 · Miss by 15.78%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.08-0.4-0.73-1.05Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual -0.98, estimate -0.64, surprise -53.12%, Miss. Q2 2025, reported May 7, 2025: actual -0.7, estimate -0.83, surprise +15.66%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.57, estimate -0.54, surprise -5.56%, Miss. Q4 2025, reported Nov 5, 2025: actual -0.38, estimate -0.54, surprise +29.63%, Beat. Q1 2026, reported Feb 24, 2026: actual -0.09, estimate -0.215, surprise +58.14%, Beat. Q2 2026, reported May 6, 2026: actual -0.4, estimate -0.355, surprise -12.69%, Miss. Q3 2026, reported Aug 6, 2026: actual -0.39, estimate -0.337, surprise -15.78%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.262, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates70.24M59.63M49.02M38.41MQ1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 26, 2025: actual 44.51M USD, estimate 44.45M USD, surprise +0.15%, Beat. Q2 2025, reported May 7, 2025: actual 41.38M USD, estimate 41.11M USD, surprise +0.64%, Beat. Q3 2025, reported Aug 7, 2025: actual 51.3M USD, estimate 52.48M USD, surprise -2.25%, Miss. Q4 2025, reported Nov 5, 2025: actual 53.78M USD, estimate 63.8M USD, surprise -15.70%, Miss. Q1 2026, reported Feb 24, 2026: actual 64.62M USD, estimate 63.8M USD, surprise +1.28%, Beat. Q2 2026, reported May 6, 2026: actual 59.88M USD, estimate 57.4M USD, surprise +4.32%, Beat. Q3 2026, reported Aug 6, 2026: actual 67.54M USD, estimate 65.79M USD, surprise +2.66%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 66.79M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$102

40.36% upside
Past 12 months12-month forecastHigh $105Average $102Low $95.00

Rating distribution

14 ratings
Strong buy00%
Buy1393%
Hold17%
Sell00%
Strong sell00%

ESTA peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ESTA

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
49.3M
Weight
0.06%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
18.09M
Weight
0.12%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
14.08M
Weight
0.08%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
First Trust Small Cap Growth AlphaDEX Fund logoFirst Trust Small Cap Growth AlphaDEX FundFYC
Market value
6.23M
Weight
0.44%
AUM
1.42B USD
Expense ratio
0.70%
Price / 1D
$122+0.71%
T. Rowe Price Small-Mid Cap ETF logoT. Rowe Price Small-Mid Cap ETFTMSL
Market value
5.83M
Weight
0.20%
AUM
3B USD
Expense ratio
0.55%
Price / 1D
$43.59+0.60%
Vanguard Health Care ETF logoVanguard Health Care ETFVHT
Market value
5.14M
Weight
0.02%
AUM
20.9B USD
Expense ratio
0.09%
Price / 1D
$327.7+1.24%
Simplify Health Care ETF logoSimplify Health Care ETFPINK
Market value
4.6M
Weight
1.21%
AUM
380.8M USD
Expense ratio
0.51%
Price / 1D
$40.21+1.16%
Invesco Dorsey Wright Healthcare Momentum ETF logoInvesco Dorsey Wright Healthcare Momentum ETFPTH
Market value
2.94M
Weight
1.09%
AUM
273.34M USD
Expense ratio
0.72%
Price / 1D
$62.9761+1.53%

Continue in GoAI

Research ESTA

research.disclaimer